Midazolam
In both cases, intravenous midazolam was used to maintain patients
asleep when they were unable to do so on their own.
Patients who did not require intravenous midazolam to achieve and/or
maintain an OAA/S score of 4 throughout the study drug infusion period
were the primary efficacy endpoints in the MAC study, whereas patients
who did not require intravenous midazolam to achieve and/or maintain an
OAA/S score of 4 throughout the study drug infusion period were the
primary efficacy endpoints in the AFOI study.
Take, for example, the genetically modified ITT population, which has a
plethora of information freely available (all randomised patients who
received the study medication and had at least one post-baseline
efficacy measurement). A statistical analysis that has been modified to
take into consideration the procedure or therapy that was received
(arteriovenous fistula, vascular stent or hernia surgery, breast
biopsies, excision of lesions and plastic surgery, ophthalmic or
orthopaedic procedures).
According to the findings of the study, dexmeditomidine was well
tolerated by patients who had AFOI or had a variety of diagnostic or
surgical procedures necessitating the administration of MAC. More
intravenous midazolam was required to maintain an RSS score of 2 in
individuals who took Dexmeditomidine compared to those who got placebo.
When Dexmeditomidine was administered in conjunction with MAC, the
majority of patients did not require intravenous midazolam to attain or
maintain an OAA/S score of 4. When it came time for cataract surgery,
the only two placebo patients in the MAC research didn’t require an
intravenous midazolam rescue sedative, which is a common practise.